Phase III trial of Skyrizi meets all endpoints in plaque psoriasis.- AbbVie
When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.
Related news and insights
UCB announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for Bimezlx (bimekizumab) for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma in patients who are not sufficiently responding to existing treatments.
Dermavant Sciences announced that new patient satisfaction data from PSOARING 3, the long-term extension study of tapinarof cream for the treatment of plaque psoriasis in adults, will be presented at the 2022 Winter Clinical Dermatology Conference, to be held Jan.